RT Journal Article SR Electronic T1 The Dual PI3K/mTOR Inhibitor BEZ235 Is Effective in Lung Cancer Cell Lines JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 849 OP 854 VO 31 IS 3 A1 VIVIAN ARRIAS HERRERA A1 EVELYN ZEINDL-EBERHART A1 ANDREAS JUNG A1 RUDOLF MARIA HUBER A1 ALBRECHT BERGNER YR 2011 UL http://ar.iiarjournals.org/content/31/3/849.abstract AB Background: BEZ235 is a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor that is orally available and that has been shown to be effective in several malignancies in vitro. Recently, BEZ235 entered clinical trials for solid tumors. We aimed at investigating if BEZ235 is effective in lung cancer cell lines. Materials and Methods: The human lung cancer cell lines EPLC, HCC and H1339 were analysed by fluorescence in situ hybridization, gene sequencing and Western blot analysis. Cells were exposed to BEZ235 and/or cisplatin and the survival fraction was quantified. Results: In all cell lines, BEZ235 reduced pAkt and pS6 expression indicating interference with the epidermal growth factor (EGF) pathway. Furthermore, BEZ235 inhibited tumor cell growth and added to the effects of cisplatin. This was independent of EGFR amplification and EGFR, KRAS, PI3K and AKT mutation. Conclusion: The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines and a promising compound to be tested in clinical phase I studies.